Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

121.10
+0.22000.18%
Post-market: 121.100.00000.00%19:52 EDT
Volume:41.42K
Turnover:5.01M
Market Cap:546.16M
PE:6.28
High:121.63
Open:120.70
Low:120.17
Close:120.88
52wk High:131.68
52wk Low:92.10
Shares:4.51M
Float Shares:4.51M
Volume Ratio:0.85
T/O Rate:0.92%
Dividend:1.12
Dividend Rate:0.93%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.64
PE(LYR):5.57

Loading ...

OverviewCompanyNewsFilings

Eli Lilly Gets Expanded Label Approval from FDA for Alopecia Drug

Dow Jones
·
Sep 26

FDA Approves Lilly's Olumiant (Baricitinib) for Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata

THOMSON REUTERS
·
Sep 26

Boston Scientific Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 26

Dow's 500-Point Rally Highlighted by Gains in Shares of Microsoft, Sherwin-Williams Co.

Dow Jones
·
Sep 26

ADARx Pharmaceuticals Shares Soar in NASDAQ Debut After Upsized IPO

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25

Novo Bets on Next Chapter While Eli Lilly Extends Its GLP-1 Dominance

Deep News
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25

J&J - Five-Year Overall Survival Rate 69.2%, Median Progression-Free Survival 60.5 Months

THOMSON REUTERS
·
Sep 25

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Imunon (IMNN)

TIPRANKS
·
Sep 25

Estee Lauder Cos. Cl a Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25
More